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Bart NK, Curtis MK, Cheng HY, Hungerford SL, McLaren R,
Petousi N, Dorrington KL, Robbins PA. Elevation of iron storage in
humans attenuates the pulmonary vascular response to hypoxia. J
Appl Physiol 121: 537–544, 2016. First published July 14, 2016;
doi:10.1152/japplphysiol.00032.2016.—Sustained hypoxia over sev-
eral hours induces a progressive rise in pulmonary artery systolic
pressure (PASP). Administration of intravenous iron immediately
prior to the hypoxia exposure abrogates this effect, suggesting that
manipulation of iron stores may modify hypoxia-induced pulmonary
hypertension. Iron (ferric carboxymaltose) administered intravenously
has a plasma half-life of 7-12 h. Thus any therapeutic use of intrave-
nous iron would require its effect on PASP to persist long after the
iron-sugar complex has been cleared from the blood. To examine this,
we studied PASP during sustained (6 h) hypoxia on 4 separate days
(days 0, 1, 8, and 43) in 22 participants. On day 0, the rise in PASP
with hypoxia was well matched between the iron and saline groups.
On day 1, each participant received either 1 g of ferric carboxymaltose
or saline in a double-blind manner. After administration of intrave-
nous iron, the rise in PASP with hypoxia was attenuated by 50%,
and this response remained suppressed on both days 8 and 43 (P 
0.001). Following administration of intravenous iron, values for fer-
ritin concentration, transferrin saturation, and hepcidin concentration
rose significantly (P  0.001, P  0.005, and P  0.001, respec-
tively), and values for transferrin concentration fell significantly (P 
0.001). These changes remained significant at day 43. We conclude
that the attenuation of the pulmonary vascular response to hypoxia by
elevation of iron stores persists long after the artificial iron-sugar
complex has been eliminated from the blood. The persistence of this
effect suggests that intravenous iron may be of benefit in some forms
of pulmonary hypertension.
hypoxia inducible factor; pulmonary hypertension; pulmonary circu-
lation
NEW & NOTEWORTHY
This study shows that a single dose of intravenous iron reduces
the effects of hypoxia on the pulmonary circulation in a manner
that persists for at least several weeks. This is long after the
foreign iron-sugar complex has been cleared from the blood. It
raises the possibility that manipulating iron stores, even in
people who are not initially iron deficient, could be used for
therapeutic gain in some forms of pulmonary hypertension.
IRON IS A TRANSITION ELEMENT essential to life. Healthy humans
have a total iron content of 4 g, about half of which is
incorporated into hemoglobin. As both Fe2 and Fe3 are
stable in solution, iron is a highly reactive participant in
oxidation-reduction reactions. This is exploited in many natu-
rally occurring examples of catalysis, but also means that free
iron is toxic, and consequently iron needs to be stored as a
complex with macromolecules.
Oxygen acts as the terminal electron acceptor for aerobic
metabolism. In large multicellular organisms, the flux of oxy-
gen generates gradients in partial pressure within the organism,
and these gradients are used to direct the development, main-
tenance, and physiological regulation of the systems for oxy-
gen transport. Important within these regulatory mechanisms is
the hypoxia-inducible factor (HIF) transcription system, which
provides a coordinated cellular response to hypoxia.
At a molecular level, the regulation of iron and oxygen is
tightly linked. Iron is an essential cofactor for the catalytic
degradation of HIF by the prolyl-hydroxylases (PHDs), and
furthermore HIF2 mRNA contains an iron-response element
(IRE) within its 5= end, so that the iron-regulatory proteins
(IRPs) can regulate the expression of HIF2 (24, 39). In a
complimentary manner, many of the proteins involved in the
regulation of iron and iron storage are themselves HIF regu-
lated (17). At the systems level, the importance of HIF to
pulmonary vascular responses to hypoxia has been demon-
strated both through experimental knockdown of the HIF
pathway in mice (3, 38), which leads to abrogation of the rise
in pulmonary arterial pressure in response to hypoxia, and
through upregulation of the HIF pathway in rare human dis-
eases and animal models of such diseases (4, 8, 27, 34), which
leads to development of pulmonary arterial hypertension.
Taken together, the above findings suggest that iron avail-
ability itself may influence the pulmonary vasculature, and
indeed this is the case. In humans, like hypoxia, iron chelation
produces a progressive rise in pulmonary arterial pressure over
a time period of 8 h (1), as indeed it does in circulating
erythropoietin (EPO), which is a classical HIF-regulated pro-
tein (20). Importantly, administration of intravenous (IV) iron
in humans abrogates the progressive rise in pulmonary arterial
pressure that occurs in response to 8 h of sustained hypoxia
(26, 33). In general, however, these experiments have focused
on the response of the pulmonary vasculature to hypoxia on the
same day as the iron administration. One exception to this is a
study where IV iron was administered to participants who had
already been at high altitude (4,340 m) for a period of 3 days
and where the reduction in pulmonary artery systolic pressure
(PASP) with iron was shown to last for a subsequent 4 days
(28). However, these participants (both treated and control)
will have had a cellular iron demand that was greatly increased
through the enhanced rate of hematopoiesis associated with
Address for reprint requests and other correspondence: P. A. Robbins, Dept.
of Physiology, Anatomy and Genetics, University of Oxford, Sherrington
Bldg., Parks Road, Oxford OX1 3PT, UK (e-mail: peter.robbins@dpag.ox.
ac.uk).
J Appl Physiol 121: 537–544, 2016.
First published July 14, 2016; doi:10.1152/japplphysiol.00032.2016.
Licensed under Creative Commons Attribution CC-BY 3.0: the American Physiological Society. ISSN 8750-7587.http://www.jappl.org 537
Downloaded from www.physiology.org/journal/jappl by ${individualUser.givenNames} ${individualUser.surname} (137.222.154.035) on May 23, 2018.
Copyright © 2016 American Physiological Society. All rights reserved.
high-altitude exposure. Overall, it remains unclear whether the
effects of iron on the pulmonary vasculature are arising as a
relatively transient phenomenon, perhaps associated with the
presence of an artificial iron-sugar complex in the blood, or
whether they are effects that persist long after the elimination
of the iron-sugar complex when the iron has been fully assim-
ilated into the body’s stores. Thus, while the close interaction
between iron and the pulmonary vasculature has been well
documented, the duration of effect of iron is unknown. Clini-
cally, this is of importance as it will determine whether or not
the effects of iron administration on the pulmonary vasculature
will persist in time.
One area where iron administration may be beneficial is in
some forms of pulmonary hypertension. In idiopathic pulmo-
nary hypertension, iron deficiency is prevalent and carries a
poorer prognosis (21, 23, 29). Supplementation of iron stores
has been shown to be of benefit in patients with pulmonary
arterial hypertension (22, 35), and further studies are underway
to further evaluate this (10). In addition, recent studies have
shown that iron deficiency is common in patients with chronic
obstructive pulmonary disease, that the iron-deficient patients
are more hypoxemic than their iron-replete counterparts, and
that the prevalence of some degree of pulmonary hypertension
is twice as great in the iron-deficient patients compared with
those who are iron replete (16, 18).
The purpose of the present study was to determine whether,
in healthy participants, the effects of iron loading on hypoxic
pulmonary vasoconstriction persist long after the iron-sugar
complex has been eliminated from the blood and when the iron
has been incorporated into the body’s stores.
METHODS
The study protocol is illustrated in Fig. 1. Participants were block
randomized (1:1) between two groups who were to receive either iron
or saline infusions, respectively. There were 4 full study days (days 0,
1, 8, and 43) in each limb of the study. Day 0 was a baseline
measurement day and occurred at least 3 days before day 1. On day
0, control measurements were made of the pulmonary vascular re-
sponses to a sustained (6 h) exposure to isocapnic hypoxia. On day 1,
participants received either a saline infusion (NaCl 0.9%) or an
infusion of 1 g of ferric carboxymaltose. Following this infusion,
participants underwent a second 6-h exposure to sustained hypoxia to
assess their pulmonary vascular response. These measurements were
repeated again at 1 wk (day 8) and 6 wk (day 43) after the saline or
iron infusion.
The study was conducted in a double-blind manner. The investi-
gator who randomized the participants, administered the infusions,
and collated the blood results was not involved in any other part of the
study. The participants were blind to the nature of the infusion as they
wore a blindfold during the infusion and the infusion port was kept out
of sight. The recruitment process, the experimental measurements,
and data analysis were conducted by an investigator who was blind to
the nature of the infusion.
Participants. Twenty-two healthy participants were studied so as to
be able to detect a difference of 4 mmHg in pulmonary artery
pressure between the two groups at a significance level of P  0.05
with a power of 80%. Participants were recruited by advertisement.
Inclusion criteria required participants to be healthy and iron replete
(ferritin 20–300 g/l, transferrin saturation 20–50%) and to have
detectable physiological tricuspid regurgitation on echocardiography
to allow for measurement of PASP. Exclusion criteria were any
significant comorbidity that may affect hematology parameters or iron
status, or pulmonary vascular or ventilatory responses. Participants
with recent exposure to an altitude2,500 m or air travel4 h within
the week prior to any experimental day were also excluded.
Each participant gave informed written consent. The study was
approved by the National Research Ethics Service Committee South
Central–Oxford A (REC 12/SC/0586) and performed in accordance
with the Declaration of Helsinki.
Iron infusion. On day 1, participants received either 50 ml of sterile
0.9% m/V NaCl (placebo group) or 1 g of iron as ferric carboxyl-
maltose (Ferinject; Vifor Pharma, Glattbrugg, Switzerland) diluted in
50-ml sterile 0.9% m/V NaCl (iron group), administered over 15 min
via a syringe infusion pump (Graseby 3100 Syringe Pump; Smiths
Medical International, Ashford, UK). Ferric carboxymaltose has a
half-life of 7.4–12.1 h (5).
Blood tests. Venous blood samples were taken on each experimen-
tal day prior to any other interventions. A full blood count together
with associated parameters was obtained through a hospital labora-
tory. Similarly, iron markers including the concentration of ferritin
and transferrin, as well as transferrin saturation, were determined by
a clinical biochemistry laboratory. In addition, enzyme-linked immu-
nosorbent assays (ELISA) were performed in duplicate on serum to
measure the concentration of EPO and interleukin 6 (IL-6) (Quan-
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Fig. 1. Protocol for the study. Twenty-two participants were recruited. Partic-
ipants were block randomized 1:1 to iron or saline. Participants were exposed
to sustained isocapnic hypoxia for 6 h on days 0, 1, 8, and 43. Day 0 was a
baseline measurement day that was undertaken at least 3 days before day 1. An
infusion of iron or saline was given on day 1.
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tikine IVD human EPO and Quantikine high-sensitivity human IL-6;
R&D Systems, Abingdon, UK) and on plasma to measure soluble
transferrin receptor concentration (sTfR) (Quantikine IVD human
sTfR; R&D Systems) and hepcidin concentration (Bachem, Peninsula
Laboratories, Torrance, CA) according to the manufacturers’ instruc-
tions.
Hypoxic exposures. The 6-h isocapnic hypoxic exposures were
conducted using a purpose-built chamber (9). The target end-tidal PO2
was 55 mmHg, and the target end-tidal PCO2 was the naturally
occurring air-breathing value for each participant, as assessed at the
beginning of each experimental day. Respired gas was sampled
continuously via a fine nasal catheter held in place at the opening of
the participant’s nostril. The samples were continually analyzed for
CO2 and O2, and the chamber gas composition was automatically
adjusted at 5-min intervals so as to minimize the difference between
the desired and measured end-tidal values for PCO2 and PO2. Partici-
Table 1. Participant demographics and baseline venous blood analyses
Variable (Normal Range) Saline Group (n  11) Iron Group (n  11) P Value
Age, yr 26.3 	 8.6 33.5 	 9.9 0.09
BMI, kg/m2 24.3 	 1.6 24.9 	 2.1 0.51
Sex Female, n  4; male, n  7 Female, n  4; male, n  7
Hemoglobin (12.0–17.0), g/dl 13.9	 1.3 14.0 	 0.9 0.81
Hematocrit (0.36–0.50) 0.42	 0.04 0.42 	 0.03 0.77
Mean cell volume (83–105), fl 93.3 	 3.8 90.8 	 5.0 0.20
Erythropoietin, IU/l 8.1	 3.4 9.3 	 3.0 0.38
Serum ferritin (10–300), g/l 66 	 40 55 	 37 0.52
Serum transferrin (1.8–3.6), g/l 2.6 	 0.4 2.7 	 0.3 0.44
Serum transferrin saturation (16–50), % 31.3 	 11.3 29.3 	 12.7 0.70
Hepcidin, g/l 51.5 	 57.9 40.2 	 34.2 0.58
sTfR, nmol/l 20.6 	 5.9 21.5 	 6.1 0.73
Interleukin-6, fg/l 0.56 	 0.41 0.56 	 0.4 0.97
C-reactive protein (0–8), mg/l 0.8 	 0.6 2.5 	 3.2 0.30
Values are means 	 SD. An unpaired two-tailed Student’s t-test was used to calculate the P value. BMI, body mass index; sTfR, soluble transferrin receptor.
Fig. 2. Hematology results. No significant effects of
infusion of 1 g of iron were detected in hemoglobin
concentration (Hb), hematocrit (Hct), or mean cell
volume (MCV). Erythropoietin concentration (EPO)
appeared mildly elevated at day 8 following iron
infusion compared with controls. Values and error
bars are means 	 SE. P values refer to the interactive
term for the change over time between groups and are
calculated using linear mixed-effects modeling. N.S, not
significant.
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pants spent no longer than 10 min in total outside of the chamber, e.g.,
for toilet breaks, over the course of a visit.
Assessment of PASP. PASP was estimated using standard echocar-
diographic techniques (27, 31) and equipment Vivid i (GE Healthcare,
Chalfont St Giles, UK). In brief, the minor (physiological) degree of
tricuspid regurgitation present in our participants resulted in a retro-
grade jet of blood from the right ventricle to the right atrium during
systole. The velocity of this jet of blood was measured using Doppler
ultrasound, and from this the peak pressure gradient across the
tricuspid valve was determined and PASP was calculated using the
modified Bernoulli’s equation, with a value of 5 mmHg assumed for
right atrial pressure (7). PASP was measured hourly during the
hypoxic exposures. One blinded investigator obtained the echocardio-
graphic images used for PASP measurements and analyzed the data.
A second blinded investigator separately analyzed a sample of the
images to check consistency of the analysis.
Statistics. Statistical analysis was conducted either using IBM
SPSS Statistics version 22.0 or using the nlme package in R
Fig. 3. Iron indexes. Following infusion of 1
g of iron, there were significant increases in
the concentration of ferritin, transferrin sat-
uration (Tsat), and hepcidin and a significant
fall in transferrin concentration (Tf). No sig-
nificant effects were observed in soluble
transferrin receptor concentration (sTfR).
Ferritin n  6 for both groups at day 43.
Values and error bars are means 	 SE. P
values refer to the interactive term for the
change over time between groups and are
calculated using linear mixed-effects model-
ing.
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(version R3.1.0; Vienna, Austria). Comparisons were drawn either
by using unpaired two-tailed Student t-tests or by using linear
mixed-effects modeling with participants as a random factor. For
the blood results, where there was one value per day, the fixed
effects were group (saline or iron), day, and the interactive term
between the two. For the measurements of PASP, the fixed effects
were group (saline or iron), day, and “state” (normoxia or sus-
tained hypoxia) (hours 4, 5, 6, where the measurements of PASP
were relatively stable), together with interactive terms. Statistical
significance was assumed at P  0.05.
RESULTS
All participants were healthy and iron replete, and their
demographics and day 0 venous blood analyses are given in
Table 1. All infusions were well tolerated. There were no major
adverse events.
Hematology variables. The two groups were well matched at
day 0 for hemoglobin concentration, hematocrit, and mean
cell volume (Table 1). These did not vary differentially over
Fig. 4. Gas control during exposure to hypoxia. A
and B: end-tidal oxygen (PETO2) levels over 6 h for
saline and iron groups, respectively. C and D: end-
tidal carbon dioxide (PETCO2) levels for saline and
iron groups, respectively. E and F: arterial hemo-
globin saturation (SpO2) for saline and iron groups,
respectively. Values and error bars are means at
each hour of hypoxia 	 SE.
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time between the saline and iron groups (Fig. 2). The groups
were similarly well matched for EPO concentration at day 0
(Table 1), but these values diverged such that EPO appeared
higher at day 8 in the iron group compared with control
(P  0.02) (Fig. 2).
Assessment of iron status. Values for the concentration of
ferritin, transferrin, transferrin saturation, hepcidin, and sTfR
were well matched between the saline and iron groups at day
0 (Table 1). Iron loading with 1 g of iron led to an acute rise
in ferritin concentration (P  0.001), transferrin saturation
(P  0.005), and hepcidin concentration (P  0.001) by day 8
(Fig. 3). These changes remained significant at day 43. Trans-
ferrin concentration fell post-iron infusion and had not returned
to preinfusion levels by day 43 (P 0.001) (Fig. 3). Values for
sTfR concentration did not differ significantly over time be-
tween the saline and iron infusion groups (Fig. 3).
Gas control during sustained hypoxic exposures. Values for
end-tidal PCO2 and PO2 were well matched between the two
groups during the hypoxic exposures in the chamber on each
experimental day (Fig. 4). Similarly, average saturation of
oxygen measured by pulse oximetry was well matched be-
tween the two groups across experimental days (Fig. 4).
PASP response to hypoxia. The responses of PASP to
hypoxia are illustrated in Fig. 5. A progressive rise in PASP
was observed in all participants over the 6-h period of hypoxia.
The interactive terms between hypoxia and group on days 1, 8,
and 43 were all significantly different from day 0 (each P 
0.001). The interactive term between hypoxia and group for
day 0 (before iron was administered) was not significant. Thus
iron significantly attenuated the PASP response to hypoxia, by
50% on day 1, and the response then remained suppressed
over the 6-wk study period.
DISCUSSION
The main finding of this study is that the suppression of the
pulmonary vascular response to sustained hypoxia following
IV administration of iron persists at 8 and 43 days after
administration. This finding demonstrates that the effects of
iron administration on the pulmonary vasculature are not sim-
ply due to the presence of a foreign iron-sugar complex in the
blood, as this is long eliminated by the 43-day time point (5).
Rather, the effect persists after the iron dose has been incor-
porated into the body’s stores of iron.
Total body iron in a normal iron-replete individual is 4 g
(15). Therefore the dose of 1 g of IV iron represents an
elevation of total body iron of25%. The loss of iron from the
body, mainly from the gut, is 1–2 mg/day (15), and in the
absence of either further iron absorption or any additional iron
loss, it will take2–3 yr for iron stores to return to preinfusion
values. In our study, apart from sTfR (itself a marker of cellular
iron demand rather than iron overload), values for the concen-
tration of plasma ferritin, transferrin, and transferrin saturation
all remained altered at 8 and 43 days post-iron infusion. What
is not clear is whether any, or all, of these indexes of iron status
will return to normal somewhat more rapidly than the rate at
which the additional iron is lost from the body or whether they
will only return to preinfusion values once the additional iron
is lost.
A similar uncertainty relates to the pulmonary vascular
response to hypoxia. It is uncertain whether this response is
related to one or more of the circulating indexes of iron status
or whether it is linked more directly to overall iron stores.
From a more clinical perspective, the real interest is that effects
of iron administration on the pulmonary vasculature are per-
sistent; they last for a long time after the iron-sugar compound
has been eliminated from the bloodstream. Thus the iron stores
of the body could potentially be manipulated artificially to
derive therapeutic gain.
Our underlying hypothesis for investigating the effects of
iron on the pulmonary vasculature has been that iron availabil-
ity affects the abundance of the transcription factor HIF, which
itself is implicated in the pulmonary vascular response to
hypoxia. While there is a very high degree of certainty both
that iron modulates the HIF pathway (1, 13, 36) and that the
HIF pathway affects the pulmonary vascular response to hyp-
oxia (3, 8, 27, 38), it nevertheless cannot be concluded with
equivalent certainty that the actions of iron availability on HIF
are indeed the mechanism by which iron affects the pulmonary
vascular response to hypoxia.
An interesting observation in our study is that the effects of
iron on PASP become apparent only after the first hour of
sustained hypoxia, and not at 1 h or before (Fig. 5). This
finding is consistent with previous work (33). Thus iron does
not appear to affect the acute (within minutes) hypoxic pulmo-
nary vascular response, but rather the second phase of inten-
sification of hypoxic pulmonary vasoconstriction, which be-
Fig. 5. Pulmonary artery systolic pressure
(PASP) during exposure to hypoxia. A and
B: PASP responses in saline and iron groups,
respectively. Responses to sustained hyp-
oxia were blunted following iron infusion on
day 1 and remained blunted at days 8 and 43
(P  0.001). Values and error bars are
means 	 SE.
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gins after 45 min and causes a further progressive rise in
PASP (32). This second slower phase of intensification has
been attributed to new gene expression triggered by hypoxia
(33), which may well be HIF regulated.
If indeed iron is working through HIF, then we may reason-
ably expect other HIF-regulated aspects of biology to be
affected by manipulation of iron stores. For example, in hu-
mans it has been shown that iron chelation increases plasma
EPO (20). However, in the present study, iron supplementation
also appeared to increase EPO (at the day 8 time point),
perhaps via a separate IRP-related effect on HIF2 (6). Fur-
thermore, there have been no reports of iron manipulation
affecting the ventilatory response to sustained hypoxia despite
the fact that HIF has been implicated in this process (12, 25,
27). This is similar to the PHD inhibitors, which have been
shown to have a marked effect on erythropoiesis but to have
minimal effects on the ventilatory response (2). Biologically,
there are many complex issues to consider. First, manipulation
of iron stores may have much greater effects on some cell types
than others. Therefore the effects of manipulating the HIF
pathway through iron stores may be specific to certain cell
types. Second, HIF1 and HIF2 quite clearly have different
actions (14, 19), and therefore it may be the case that iron has
differential effects in relation to these two isoforms (11, 30).
Third, although the classical effect of iron on the HIF pathway
is through its involvement in the catalytic hydroxylation of HIF
by the PHD enzymes, it has also been shown that cellular iron
status affects the translation of HIF2 through the presence of
an IRE in the 5= end of the HIF2 mRNA (6, 24, 37). Again,
this is a potential mechanism that could underlie both cell-
specific and isoform-specific actions of iron on the HIF path-
way.
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